NTI drug with high CV? [Power / Sample Size]

posted by Helmut Homepage – Vienna, Austria, 2019-12-14 17:11 (1580 d 20:09 ago) – Posting: # 20976
Views: 2,407

Hi Mikalai,

❝ What would be a sample size for a BE study when the CV of the drug is 30% but bioequivalence should be in range 90_110%?


Unless the drug belongs to the last generation anticoagulants (dabigatran, rivaroxaban) that's a contradiction. NTIDs show low variability. Otherwise, there would have been serious problems in phase III: toxicity, lacking efficacy – no approval – end of story.
BTW, the acceptance limits for NTIDs in the EEA are 90.00–111.11%.

❝ Our assumption is around 400 subject if the design is standard, and 200 if the design is replicative


library(PowerTOST)
sampleN.TOST(CV = 0.3, theta1 = 0.9, design = "2x2x2")
sampleN.TOST(CV = 0.3, theta1 = 0.9, design = "2x2x4")

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,980 posts in 4,821 threads, 1,659 registered users;
27 visitors (0 registered, 27 guests [including 10 identified bots]).
Forum time: 14:20 CEST (Europe/Vienna)

Never, never, never use any software!
Never, never, never trust any computer!    Detlew Labes

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5